Shionogi & Co. is pursuing at least three acquisition opportunities and weighing an expansion of US manufacturing capacity as it looks to diversify production and reduce geopolitical risk over the next decade, according to Bloomberg. The Japanese drugmaker is seeking to broaden its footprint while shifting more of its supply base outside Japan.